Skip to main content

Advertisement

SpringerLink
Log in

Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry

  • Original Article
  • Published:
Familial Cancer Aims and scope Submit manuscript

Abstract

To determine the validity of observations suggesting a significant dichotomy of gynecologic cancers determined by linkage to specific genetic defects associated with two major autosomal dominant hereditary cancer syndromes; the Creighton University Hereditary Cancer Registry was searched for female carriers of germ line mutations in BRCA1 and BRCA2, associated with the Hereditary Breast Ovarian Cancer syndrome, and in the mismatch repair (MMR) genes MLH1, MSH2 and MSH6, associated with Lynch syndrome, who were registered with invasive uterine, ovarian, fallopian tube or peritoneal cancers between January 1, 1959 and December 31, 2010. From 217 such cases, a total of 174 subjects, consisting of 95 BRCA1 and BRCA2 mutation carriers and 79 carriers of mutations in MMR genes, were identified who had current signed Health Insurance Portability and Accountability Act forms and complete primary diagnostic pathology reports and clinical records. Data meticulously extracted from these cases were categorized and statistically analyzed. There were highly significant differences between carriers of BRCA1 and BRCA2 mutations and carriers of MMR gene mutations in the proportion of serous carcinomas compared with endometrioid carcinomas of the uterus, including cervix and endometium (p < 0.002), ovaries (p < 0.001) and overall, including fallopian tube and peritoneum cancers (p < 0.001). Endometrioid carcinoma was found in one and transitional carcinoma in another of the 14 BRCA1 mutation carriers with fallopian tube cancer, and endometrioid carcinoma was found in two of four MMR gene mutation carriers with fallopian tube cancers. All other fallopian tube cancers were serous carcinomas. Seven BRCA1 and one BRCA2 mutation carriers were diagnosed with primary peritoneal serous carcinoma; no peritoneal carcinomas were registered in MMR gene mutation carriers. Nine of 14 gynecologic cancers with associated endometriosis in mutation carriers were endometrioid or endometrioid mixed carcinomas compared with just three of other histologic types. Primary breast cancers, that characterize the HBOC syndrome, were much more frequent in BRCA1 and BRCA2 mutation carriers; while multiple gynecologic cancers and associated colorectal and urinary tract cancers, which are features of Lynch syndrome, were more common in MMR gene mutation carriers. Both serous and endometrioid carcinomas were diagnosed in MMR gene mutation carriers at significantly younger ages than in BRCA1 and BRCA2 mutation carriers (p < 0.0006). These findings confirm a clear dichotomy of uterine, ovarian and fallopian tube cancers associated with inheritance of mutations in BRCA1 and BRCA2 contrasted with inheritance of MMR gene mutations. This opens possibilities for new approaches to molecular genetic research into carcinogenic pathways and raises important new considerations regarding counseling, screening, prophylaxis and treatment of mutation carriers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. American Cancer Society (2013) Cancer Facts and Figures 2013. American Cancer Society, Atlanta

    Google Scholar 

  2. Claus EB, Schildkraut JM, Thompson WD, Risch NJ (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77:2318–2324

    CAS  PubMed  Google Scholar 

  3. Boyd J (1998) Molecular genetics of hereditary ovarian cancer. Oncology 12:399–406

    CAS  PubMed  Google Scholar 

  4. Rubin SC, Blackwood MA, Bandera C, Behbakht K, Benjamin I, Rebbeck TR, Boyd J (1998) BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer populations: relationship to family history and implications for genetic testing. Am J Obstet Gynecol 178:670–677

    CAS  PubMed  Google Scholar 

  5. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H et al (2005) BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104:2807–2816

    CAS  PubMed  Google Scholar 

  6. Bewtra C, Watson P, Conway T, Read-Hippee C, Lynch HT (1992) Hereditary ovarian cancer: a clinicopathological study. Int J Gynecol Pathol 11:180–187

    CAS  PubMed  Google Scholar 

  7. Malander S, Rambech E, Kristoffersson U, Halvarsson B, Ridderheim M, Borg A, Nilbert M (2006) The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer. Gynecol Oncol 101:238–243

    CAS  PubMed  Google Scholar 

  8. Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M, Godwin AK (2009) Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol 3:97–137

    CAS  PubMed  Google Scholar 

  9. Lynch HT, Casey MJ, Lynch J, White TEK, Godwin AK (1998) Genetics and ovarian carcinoma. Sem Oncol 25:265–281

    CAS  Google Scholar 

  10. Watson P, Bützow R, Lynch HT, Mecklin JP, Järvinen HJ, Vasen HF et al (2001) International collaborative group on HNPCC. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 82:223–228

    CAS  PubMed  Google Scholar 

  11. Creasman WT, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz APM et al (2006) Carcinoma of the corpus uteri. Int J Gynecol Obstet 95(Suppl 1):S105–S143

    Google Scholar 

  12. Parazzini F, La Vecchia C, Moroni S, Chatenoud L, Ricci E (1994) Family history and the risk of endometrial cancer. Int J Cancer 59:460–462

    CAS  PubMed  Google Scholar 

  13. Gruber SB, Thompson WD (1996) A population-based study of endometrial cancer and familial risk in younger women. Cancer and Steroid Hormone Study Group. Cancer Epidemiol Biomarkers Prev 5:411–417

    CAS  PubMed  Google Scholar 

  14. de la Chapelle A (2005) The incidence of Lynch syndrome. Fam Cancer 4:233–237

    PubMed  Google Scholar 

  15. Hampel H, Frankel W, Panescu J, Lockman J, Sotamaa K, Fix D et al (2006) Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 66:7810–7817

    CAS  PubMed  Google Scholar 

  16. Lynch HT, Casey MJ, Knezetic JA, Shaw TG, Lynch JF, Bewtra C (2007) Hereditary factors in endometrial cancer. In: Giordano A, Bovicelli A, Kurman RJ (eds) Molecular pathology of gynecologic cancer. Humana Press, New Jersey, Totowa, pp 195–215

    Google Scholar 

  17. Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD et al (2008) The clinical phenotype of Lynch syndrome due to PMS2 mutations. Gastroenterology 135:419–428

    CAS  PubMed  Google Scholar 

  18. Baglietto L, Lindor NM, Dowty JG, White DM, Wagner A, Gomez Garcia EB et al (2010) Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst 102:193–201

    CAS  PubMed  Google Scholar 

  19. Bokhman JV (1983) Two pathologic types of endometrial carcinoma. Gynecol Oncol 15:10–17

    CAS  PubMed  Google Scholar 

  20. Mutter GL (2007) Endometrial carcinogenesis. In: Giordano A, Bovicelli A, Kurman R (eds) Molecular pathology of gynecologic cancer. Humana Press, Totowa, pp 73–90

    Google Scholar 

  21. Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ (1992) Uterine serous carcinoma: a morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 16:600–610

    CAS  PubMed  Google Scholar 

  22. Casey MJ, Bewtra C (2004) Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations. Fam Cancer 3:265–681

    CAS  PubMed  Google Scholar 

  23. Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT et al (2006) Carcinoma of the cervix uteri. Int J Gynecol Obstet 95(Suppl 1):S43–S103

    Google Scholar 

  24. Vaknin Z, Gotlieb WH, Arseneau J, Ferenczy A (2009) Papillary serous carcinoma in situ in ovarian endometriosis in an MSH2 mutation carrier. Int J Gynecol Obstet 107:68–69

    Google Scholar 

  25. Nyiraneza C, Marbaix E, Smets M, Galant C, Sempoux C, Dahan K (2010) High risk for neoplastic transformation of endometriosis in a carrier of lynch syndrome. Fam Cancer 9:383–387

    PubMed  Google Scholar 

  26. Narod SA, Ford D, Devilee P, Barkardottir RB, Lynch HT, Smith SA et al (1995) An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet 56:254–264

    CAS  PubMed  Google Scholar 

  27. Easton DF, Ford D, Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1 mutation carriers. The Breast Cancer Linkage Consortium. Am J Hum Genet 56:265–271

    CAS  PubMed  Google Scholar 

  28. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Deville P et al (1998) Genetic heterogeneity and penetrance analysis of BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676–689

    CAS  PubMed  Google Scholar 

  29. Goodfellow PJ, Buttin BM, Herzog TJ, Rader JS, Gibb RK, Swisher E et al (2003) Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci 100:5908–5913

    CAS  PubMed  Google Scholar 

  30. Cederquist K, Emanuelsson M, Göransson I, Holinski-Feder E, Müller-koch Y, Golovleva I, Grönberg H (2004) Mutation analysis of the MLH1, MSH2 and MSH6 genes in patients with double primary cancers of the colorectum and the endometrium: a population-based study in northern Sweden. Int J Cancer 109:370–376

    CAS  PubMed  Google Scholar 

  31. National Center for Biotechnology Information. Gene. National Institutes of Health. Available at: http://www.ncbi.nlm.nih.gov/gene? term = Lynch%20syndrome (Accessed on 10 Feb 2011)

  32. Zhou C, Gilks CB, Hayes M, Clement PB (1998) Papillary serous carcinoma of the uterine cervix: a clinicopathologic study of 17 cases. Am J Surg Pathol 22:113–120

    CAS  PubMed  Google Scholar 

  33. Young RH, Clement PB (2002) Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis. Histopathology 41:185–207

    CAS  PubMed  Google Scholar 

  34. Kaplan EJ, Caputo TA, Shen PUF, Sassoon RI, Soslow RA (1998) Familial papillary serous carcinoma of the cervix, peritoneum and ovary: a report of the first case. Gyncol Oncol 70:289–294

    CAS  Google Scholar 

  35. Nair N, Curtin JP, Mittal K, Hiotis KL (2012) Cervical adenocarcinoma in a patient with Lynch syndrome, Muir-Torre variant. J Clin Oncol 30:e5–e6

    PubMed  Google Scholar 

  36. Nyström-Lahti M, Parsons R, Sistonen P, Pylkkänen L, Aaltonen LA, Leach FS et al (1994) Mismatch repair genes on chromosomes 2p and 3p account for a major share of hereditary nonpolyposis colorectal cancer families evaluable by linkage. Am J Hum Genet 55:659–665

    PubMed  Google Scholar 

  37. Mongiat-Artus P, Miquel C, Fléjou J-F, Coulet F, Verine J, Buhard O et al (2006) Spectrum of molecular alterations in colorectal, upper urinary tract, endocervical, and renal carcinomas arising in a patient with hereditary non-polyposis colorectal cancer. Virchows Arch 449:238–243

    PubMed  Google Scholar 

  38. Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J et al (1997) Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6:105–110

    CAS  PubMed  Google Scholar 

  39. Vasen HFA, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G et al (2001) MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 19:4074–4080

    CAS  PubMed  Google Scholar 

  40. Quehenberger F, Vasen HF, van Houweligen HC (2005) Risk of colorectal and endometrial cancer for carriers of mutations of the hMH1 and hMSH2 gene: correction for ascertainment. J Med Genet 42:491–496

    CAS  PubMed  Google Scholar 

  41. Boks DES, Trujillo AP, Voogd AC, Morreau H, Kenter G, Vasen HFA (2002) Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. Int J Cancer 102:198–200

    CAS  PubMed  Google Scholar 

  42. Broaddus RR, Lynch HT, Chen L-M, Daniels MS, Conrad P, Munsell MF et al (2006) Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer 106:87–94

    CAS  PubMed  Google Scholar 

  43. Thompson D, Easton DF, Breast Cancer Linkage Consortium (2002) Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358–1365

    CAS  PubMed  Google Scholar 

  44. Hornreich G, Beller U, Lavie O, Renbaum P, Cohn Y, Levy-Lahad E (1999) Is uterine serous carcinoma a BRCA1-related disease? Case report and review of the literature. Gynecol Oncol 75:300–304

    CAS  PubMed  Google Scholar 

  45. Lavie O, Hornreich G, Ben-Arie A, Rennert G, Cohen Y, Keidar R et al (2004) BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol 92:521–524

    CAS  PubMed  Google Scholar 

  46. Lavie O, Ben-Arie A, Pilip A, Rennert G, Cohen Y, Feiner B, Ausinader R (2005) BRCA2 germline mutation in a woman with uterine serous papillary carcinoma: case report. Gynecol Oncol 99:486–488

    PubMed  Google Scholar 

  47. Biron-Shental T, Drucker L, Altaras M, Bernheim J, Fishman A (2006) High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma. Eur J Surg Oncol 32:1097–1100

    CAS  PubMed  Google Scholar 

  48. Bruchim I, Amichay K, Kidron D, Attias Z, Biron-Shental T, Drucker L et al (2010) BRCA1/2 germline mutations in Jewish patients with uterine serous carcinoma. Int J Gynecol Cancer 20:1148–1153

    PubMed  Google Scholar 

  49. Lavie O, Ben-Arie A, Segev Y, Faro J, Barak F, Haya N et al (2010) BRCA mutations in women with uterine serous carcinoma-still a debate. Int J Gynecol Cancer 20:1531–1534

    PubMed  Google Scholar 

  50. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ (1995) Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 26:1260–1267

    CAS  PubMed  Google Scholar 

  51. Zheng W, Schwartz PE (2005) Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management. Gynecol Oncol 96:579–582

    PubMed  Google Scholar 

  52. Sherman ME, Bur ME, Kurman RJ (1995) p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 26:1268–1274

    CAS  PubMed  Google Scholar 

  53. Zheng W, Xiang L, Fadare O, Kong B (2011) A proposed model for endometrial serous carcinogenesis. Am J Surg Pathol 35:e1–e14

    PubMed  Google Scholar 

  54. Silva EG, Jenkins R (1990) Serous carcinoma in endometrial polyps. Mod Pathol 3:120–128

    CAS  PubMed  Google Scholar 

  55. Lee KR, Belinson JL (1991) Recurrence in noninvasive endometrial carcinoma: relationship to uterine papillary serous carcinoma. Am J Surg Pathol 15:965–973

    CAS  PubMed  Google Scholar 

  56. Goff BA, Kato D, Schmidt RA, Ek M, Ferry JA, Muntz HG et al (1994) Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 54:264–268

    CAS  PubMed  Google Scholar 

  57. Kupryjanczyk J, Thor AD, Beauchamp R, Poremba C, Scully RE, Yandell DW (1996) Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease. Mod Pathol 9:166–173

    CAS  PubMed  Google Scholar 

  58. Carcangiu ML, Tan LK, Chambers JT (1997) Stage IA uterine serous carcinoma: a study of 13 cases. Am J Surg Pathol 21:1507–1514

    CAS  PubMed  Google Scholar 

  59. Soslow RA, Pirog E, Isacson C (2000) Endometrial intraepithelial carcinoma with associated peritoneal carcinomatosis. Am J Surg Pathol 24:726–732

    CAS  PubMed  Google Scholar 

  60. Wheeler DT, Bell JA, Kurman RJ, Sherman ME (2000) Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Path 24:797–806

    CAS  PubMed  Google Scholar 

  61. Baergen RN, Warren CD, Isacson C, Ellenson LH (2001) Early uterine serous carcinoma: clonal origin of extrauterine disease. Int J Gynecol Pathol 20:214–219

    CAS  PubMed  Google Scholar 

  62. Slomovitz BM, Burke TW, Eifel PJ, Ramondetta LM, Silva EG, Jhingran A et al (2003) Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 91:463–469

    PubMed  Google Scholar 

  63. Massuger L, Roelofsen T, van Ham M, Bulten J (2010) The origin of serous ovarian cancer may be found in the uterus: a novel hypothesis. Med Hypothesis 74:859–861

    Google Scholar 

  64. Roelofsen T, van Kempen LC, van der Laak JA, van Ham MA, Bulten J, Massuger LF (2012) Concurrent endometrial intraepithelial carcinoma (EIC) and serous ovarian cancer: can EIC be seen as the precursor lesion? Int J Gynecol Cancer 22:457–464

    PubMed  Google Scholar 

  65. Heintz APM, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HYS, Pecorelli S (2006) Carcinoma of the ovary. Int J Gynecol Obstet 95(Suppl 1):161–192

    Google Scholar 

  66. Ketabi Z, Bartuma K, Bernstein I, Malander S, Grönberg H, Björck E et al (2011) Ovarian cancer linked to Lynch syndrome typically presents as early-onset non-serous epithelial tumors. Gynecol Oncol 121:462–465

    PubMed  Google Scholar 

  67. Heintz APM, Odincino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT et al (2006) Carcinoma of the fallopian tube. Int J Gynecol Obstet 95(Suppl 1):145–160

    Google Scholar 

  68. Young RH (2007) Neoplasms of the fallopian tube and broad ligament: a selective survey including historical perspective and emphasizing recent developments. Pathology 39:112–124

    PubMed  Google Scholar 

  69. Culton LK, Deavers MT, Silva EG, Liu J, Malpica A (2006) Endometrioid carcinoma simultaneously involving the uterus and the fallopian tube. Am J Surg Pathol 30:844–849

    PubMed  Google Scholar 

  70. Roh MH, Kindelberger D, Crum CP (2009) Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin? Am J Surg Pathol 33:376–383

    PubMed  Google Scholar 

  71. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C et al (2006) The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30:230–236

    PubMed  Google Scholar 

  72. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F et al (2007) Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 31:161–169

    PubMed  Google Scholar 

  73. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A et al (2007) A candidate to serous carcinoma that originates in the distal fallopian tube. J Pathol 211:26–35

    CAS  PubMed  Google Scholar 

  74. Folkins AK, Jarboe EA, Roh MH, Crum CP (2009) Precursors to pelvic serous carcinoma and their clinical implications. Gynecol Oncol 113:391–396

    PubMed  Google Scholar 

  75. Zweemer RP, van Diest PJ, Verheijen RH, Ryan A, Gille JJ, Sijmons RH et al (2000) Molecular evidence linking primary cancer of the fallopian tube to BRCA1 mutations. Gynecol Oncol 76:45–50

    CAS  PubMed  Google Scholar 

  76. Cass I, Holschneider C, Datta N, Barbuto D, Walts AE, Karlan BY (2005) BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol 106:1327–1334

    CAS  PubMed  Google Scholar 

  77. Powell CB, Kenley E, Chen L, Crawford B, McLennan J, Zaloudek C et al (2005) Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 23:127–132

    PubMed  Google Scholar 

  78. Carcangui ML, Peissel B, Pasini B, Spatti G, Radice P, Manoukian S (2006) Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. Am J Surg Pathol 30:1222–1230

    Google Scholar 

  79. Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ (2006) Clinical and pathological findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gyencol Oncol 100:58–64

    CAS  Google Scholar 

  80. Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE et al (2007) Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 25:3985–3990

    PubMed  Google Scholar 

  81. Palma L, Marcus V, Gilbert L, Chong G, Foulkes WD (2008) Synchoronous occult cancers of the endometrium and fallopian tube in an MSH2 mutation carrier at the time of prophylactic surgery. Gynecol Oncol 111:575–578

    PubMed  Google Scholar 

  82. Schmeler KM, Daniels MS, Soliman PT, Broaddus RR, Deavers MT, Vu TM et al (2010) Primary peritoneal cancer after bilateral salpingo-oophorectomy in two patients with Lynch syndrome. Obstet Gynecol 115:432–434

    PubMed  Google Scholar 

  83. Lynch HT, Krush AJ, Lemon HM, Kaplan AR, Condit PT, Bottomley RH (1972) Tumor variation in families with breast cancer. JAMA 222:1631–1635

    CAS  PubMed  Google Scholar 

  84. Lynch HT, Lynch PM (1979) Tumor variation in the cancer family syndrome: ovarian cancer. Am J Surg 138:439–442

    CAS  PubMed  Google Scholar 

  85. Lynch HT, Ens J, Lynch JF, Watson P (1988) Tumor variation in three extended Lynch syndrome II kindreds. Am J Gastroenterol 83:741–747

    CAS  PubMed  Google Scholar 

  86. Lynch HT, Guirgis HA, Albert S, Brennan M, Lynch J, Kraft C et al (1974) Familial association of carcinoma of the breast and ovary. Surg Gynecol Obstet 138:717–724

    CAS  PubMed  Google Scholar 

  87. Narod SA, Feuteun J, Lynch HT, Watson P, Conway T, Lenoir GM (1991) Familial breast-ovarian cancer locus on chromosome 17q12–23. Lancet 388:82–83

    Google Scholar 

  88. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N et al (1994) Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–13. Science 265:2088–2090

    CAS  PubMed  Google Scholar 

  89. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–792

    CAS  PubMed  Google Scholar 

  90. Liang SX, Pearl M, Liang S, Xiang L, Jia L, Yang B et al (2001) Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old and younger. Int J Cancer 128:763–770

    Google Scholar 

  91. Geary J, Sasieni P, Houlston R, Izatt L, Eeles R, Payne SJ et al (2008) Gene-related cancer spectrum in families with hereditary colorectal cancer (HNPCC). Fam Cancer 7:163–172

    CAS  PubMed  Google Scholar 

  92. Watson P, Vasen HFA, Mecklin J-P, Bernstein I, Aarnio M, Järvinen HJ et al (2008) The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 123:444–449

    CAS  PubMed  Google Scholar 

  93. Buerki N, Gautier L, Kovac M, Marra G, Buser M, Mueller H, Heinimann K (2012) Evidence for breast cancer as an integral part of Lynch syndrome. Genes Chromosomes Cancer 51:83–91

    CAS  PubMed  Google Scholar 

  94. Zaino R, Whitney C, Brady MF, DeGeest K, Burger RA, Buller RE (2001) Simultaneously detected endometrial and ovarian carcinomas: a prospective clinicopathologic study of 74 cases: a Gynecologic Oncology Group study. Gynecol Oncol 83:355–362

    CAS  PubMed  Google Scholar 

  95. Hemminki K, Aaltonen L, Li X (2003) Subsequent primary malignancies after endometrial carcinoma and ovarian carcinoma. Cancer 97:2432–2439

    PubMed  Google Scholar 

  96. Uccella S, Cha SS, Melton LJ, Bergstralh EJ, Boardman LA, Keeney GL et al (2011) Risk factors for developing multiple malignancies in patients with endometrial cancer. Int J Gynecol Cancer 21:896–901

    PubMed  Google Scholar 

  97. Aarnio M, Mecklin J-P, Aaltonen LA, Nyström-Lahti M, Järvinen HJ (1995) Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 64:430–433

    CAS  PubMed  Google Scholar 

  98. Vasen HFA, Wijnen HTh, Menko FH, Kleibeuker JH, Taal BG, Griffioen G et al (1996) Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroentology 110:1020–1027

    CAS  Google Scholar 

  99. Green J, O’Driscoll M, Barnes A, Maher ER, Bridge P, Shields K, Parfrey PS (2002) Impact of gender and parent of origin on the phenotypic expression of hereditary nonpolyposis colorectal cancer in a large Newfoundland kindred with a common MSH2 mutation. Dis Colon Rectum 45:1223–1232

    PubMed  Google Scholar 

  100. Hendriks YMC, Wagner A, Morreau H, Menko F, Stomorken A, Quehenberger F et al (2004) Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 127:17–25

    CAS  PubMed  Google Scholar 

  101. Vasen HFA, Watson P, Mecklin J-P, Jass JR, Green JS, Nomizu T et al (1994) The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer. Anticancer Res 14:1675–1678

    CAS  PubMed  Google Scholar 

  102. Lu KH, Dinh M, Kohlmann W, Watson P, Green J, Syngal S et al (2005) Gynecologic cancer as a “sentinel cancer” for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 105:569–574

    PubMed  Google Scholar 

  103. Vasen HFA, Offerhaus GJ, den Hartog Jager FC, Menko FH, Nagengast FM, Griffioen G et al (1990) The tumor spectrum in hereditary nonpolyposis colorectal cancer: a study of 24 kindreds in the Netherlands. Int J Cancer 46:31–34

    CAS  PubMed  Google Scholar 

  104. Watson P, Lynch HT (1993) Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 71:677–685

    CAS  PubMed  Google Scholar 

  105. van der Post RS, Kiemeney LA, Ligtenberg MJL, Witjes JA, Hulsbergen-van de Kaa CA, Bodmer D et al (2010) Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet 47:464–470

    PubMed  Google Scholar 

  106. Swiersz L (2002) Role of endometriosis in cancer and tumor development. Ann NY Acad Sci 955:281–292

    PubMed  Google Scholar 

  107. Varma R, Rollason T, Gupta JK, Maher ER (2004) Endometriosis and the neoplastic process. Reproduction 127:293–304

    CAS  PubMed  Google Scholar 

  108. Somigliana E, Viganò P, Parazzini F, Stoppelli S, Giambattista E, Vercellini P (2006) Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecol Oncol 101:331–341

    PubMed  Google Scholar 

  109. Viganò P, Somigliana E, Parazzini F, Vercellini P (2007) Bias versus causality: interpreting recent evidence of association between endometriosis and ovarian cancer. Fertil Steril 88:588–593

    PubMed  Google Scholar 

  110. Nezhat F, Datta MS, Hanson V, Pejovic T, Nezhat C, Nezhat C (2008) The relationship of endometriosis and ovarian malignancy: a review. Fertil Steril 90:1559–1570

    CAS  PubMed  Google Scholar 

  111. Munksgaard PS, Blaakaer J (2011) The association between endometriosis and gynecologic cancers and breast cancer: a review of epidemiological data. Gyencol Oncol 123:157–163

    Google Scholar 

  112. Munksgaard PS, Blaakaer J (2012) The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecol Oncol 124:164–169

    CAS  PubMed  Google Scholar 

  113. Wei J–J, William J, Bulun S (2011) Endometriosis and ovarian cancer: a review of clinical, pathological, and molecular aspects. Int J Gynecol Pathol 30:553–568

    PubMed  Google Scholar 

  114. Brinton LA, Gridley G, Persson I, Baron J, Bergqvist A (1997) Cancer risk after hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol 176:572–579

    CAS  PubMed  Google Scholar 

  115. Borgfeldt C, Andolf E (2004) Cancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis. Acta Obstet Gynecol Scand 83:395–400

    PubMed  Google Scholar 

  116. Heaps JM, Nieberg RK, Berek JS (1990) Malignant neoplasms arising in endometriosis. Obstet Gynecol 75:1023–1028

    CAS  PubMed  Google Scholar 

  117. McMeekin DS, Burger RA, Manetta A, DiSaia P, Berman ML (1995) Endometrioid adenocarcinoma of the ovary and its relationship to endometriosis. Gynecol Oncol 59:81–86

    CAS  PubMed  Google Scholar 

  118. Sainz de la Cuesta R, Eichhorn JH, Rice LW, Fuller AR Jr, Nikrui N, Goff BA (1996) Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol 60:238–244

    CAS  PubMed  Google Scholar 

  119. Fukunaga M, Nomura K, Ishikawa E, Ushigome S (1997) Ovaian atypical endometriosis: its close association with malignant epithelial tumours. Histopathology 30:249–255

    CAS  PubMed  Google Scholar 

  120. Erzen M, Kovacic J (1998) Relationship between endometriosis and ovarian cancer. Euro J Gynaecol Oncol 19:553–555

    CAS  Google Scholar 

  121. Slavin RE, Krum R, Van Dihn T (2000) Endometriosis–associated intestinal tumors: a clinical and pathological study of 6 cases with review of the literature. Hum Pathol 31:456–463

    CAS  PubMed  Google Scholar 

  122. Stern RC, Dash R, Bentley RC, Snyder MJ, Haney AF, Robboy SJ (2001) Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol 20:133–139

    CAS  PubMed  Google Scholar 

  123. Modesitt SC, Tortolero-Luna G, Robinson JB, Gershenson DM, Wolf JK (2002) Ovarian and extraovarian endometriosis-associated cancer. Obstet Gynecol 100:788–795

    PubMed  Google Scholar 

  124. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM et al (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 13:385–394

    PubMed  Google Scholar 

  125. Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT (2005) Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol 97:457–467

    PubMed  Google Scholar 

  126. Fraumeni LS Jr, Grundy GW, Creagan ET, Everson RB (1975) Six families prone to ovarian cancer. Cancer 36:364–369

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Obstetrics and Gynecology and Preventive Medicine, Creighton University School of Medicine, Omaha, NE, USA

    Murray Joseph Casey

  2. Department of Pathology, Creighton University School of Medicine, Omaha, NE, USA

    Chhanda Bewtra

  3. Department of Preventive Medicine, Creighton University School of Medicine, Omaha, NE, USA

    Murray Joseph Casey, Henry T. Lynch, Carrie Snyder & Mark Stacy

  4. Departments of Preventive Medicine and Medicine, Creighton University School of Medicine, Omaha, NE, USA

    Patrice Watson

  5. Department of Obstetrics and Gynecology, Creighton University Women’s Health Center, 601 North 30th Street, Suite 4700, Omaha, NE, 68131, USA

    Murray Joseph Casey

Authors
  1. Murray Joseph Casey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chhanda Bewtra
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Henry T. Lynch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carrie Snyder
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mark Stacy
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Patrice Watson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Murray Joseph Casey.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Casey, M.J., Bewtra, C., Lynch, H.T. et al. Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry. Familial Cancer 12, 719–740 (2013). https://doi.org/10.1007/s10689-013-9651-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10689-013-9651-x

Keywords

Search

Navigation